Martin AA, Tomas FM, Owens PC, Knowles SE, Ballard FJ, Read LC: IGF-I and its variant, des-(13)IGF-I, enhance growth in rats with reduced renal mass
This case highlights how pharmacologic agents like GLP1 receptor agonists (that are often assumed to be benign), can carry unexpected risks in the presence of overlapping vulnerabilities, such as OSA and CPAP use
In addition to taking either semaglutide or placebo for the trial, all participants also received standard-of-care treatment for cardiovascular disease, such as cholesterol-modifying medications, antiplatelet therapies, beta blockers or other treatments
By coupling brain-targeted nanocarriers with patient-specific metabolic fingerprints, a gene-matched, pathway-matched strategy is emergingpositioning riboflavin at the center of personalized, systems-level interventions for both rare flavoproteinopathies and common neurodegenerative disorders
However, mixing these two substances can be dangerous, primarily due to how they affect the liver
Everyone is so kind, helpful and especially knowledgeable